Williamson Legacy Group LLC Has $1.27 Million Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Williamson Legacy Group LLC lifted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 1.7% in the 4th quarter, Holdings Channel reports. The institutional investor owned 57,824 shares of the company’s stock after acquiring an additional 979 shares during the period. Teva Pharmaceutical Industries accounts for about 0.8% of Williamson Legacy Group LLC’s portfolio, making the stock its 26th biggest position. Williamson Legacy Group LLC’s holdings in Teva Pharmaceutical Industries were worth $1,274,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of TEVA. Smithfield Trust Co grew its position in shares of Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after buying an additional 980 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $50,000. Venturi Wealth Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $60,000. Ameliora Wealth Management Ltd. acquired a new position in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $66,000. Finally, Farther Finance Advisors LLC grew its holdings in Teva Pharmaceutical Industries by 273.5% during the third quarter. Farther Finance Advisors LLC now owns 4,538 shares of the company’s stock valued at $82,000 after purchasing an additional 3,323 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Up 0.8 %

Teva Pharmaceutical Industries stock opened at $16.45 on Friday. The stock has a market capitalization of $18.64 billion, a PE ratio of -11.34, a price-to-earnings-growth ratio of 1.44 and a beta of 0.71. Teva Pharmaceutical Industries Limited has a twelve month low of $12.51 and a twelve month high of $22.80. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The company has a 50 day moving average of $19.65 and a 200-day moving average of $18.46.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Analyst Ratings Changes

TEVA has been the subject of a number of analyst reports. StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. UBS Group decreased their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, January 30th. Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. Finally, Barclays decreased their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $23.57.

Insider Transactions at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now owns 695,000 shares of the company’s stock, valued at $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.55% of the stock is currently owned by insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.